Claims for Patent: 7,592,161

Summary for Patent: 7,592,161

Title:	Methods for analyzing the insertion capabilities of modified group II introns
Abstract:	The present invention provides a system and methods for analyzing the function of nucleotide integrases and modified group II introns. The system comprises a donor plasmid comprising a wild-type or modified group II intron, a recipient plasmid comprising a DNA recognition site and a promoterless reporter gene downstream of the DNA target site, and a host cell. The method comprises the steps of transforming a host cell with the donor and recipient plasmids, assaying for expression of the reporter gene, isolating plasmid DNA from the cotransformed cells, and analyzing the plasmid DNA to confirm that the group II intron has been inserted into the target sequence. The present invention also provides a method for simultaneously analyzing the activity of two or more modified nucleotide integrases. The present invention also relates to methods of preparing a library of donor plasmids containing a plurality of diverse modified group II intron DNA sequences.
Inventor(s):	Lambowitz; Alan M. (Austin, TX), Guo; Huatao (Alhambra, CA), Karberg; Michael (Austin, TX)
Assignee:	The Ohio State University Research Foundation (Columbus, OH) The University of Texas Board of Regents of the University of Texas System (Austin, TX)
Application Number:	10/277,643
Patent Claims:	1. A method of increasing insertion of modified group II introns into a DNA target site in a host cell in vitro, comprising: a) introducing a nucleic acid construct into the host cell, said construct comprising: i.) a modified group II intron sequence encoding a modified group II intron RNA, said modified group II intron RNA comprising an EBS1 sequence, an EBS2 sequence, a delta sequence, and a deletion of subdomains IVB1, IVB2, IVB3, wherein one or more of said EBS1, EBS2 or delta sequences is modified to provide a modified EBS1, EBS2, and delta sequence that base pairs with an IBS1, IBS2, and delta prime sequence, respectively, in the DNA target site; ii) a promoter for regulating transcription of said modified group II intron sequence, said promoter being operably linked to the modified group II intron sequence; iii) a first flanking sequence upstream of the modified group II intron sequence, said flanking sequence encoding a first hybridizing sequence which is complementary to the EBS1 or the modified EBS1 sequence contained in said modified group II intron RNA, and a second flanking sequence downstream of the modified group II intron sequence encoding a second hybridizing sequence which is complementary to the EBS2 or the modified EBS2 sequence contained in said modified group II intron RNA; and iv) an open reading frame sequence encoding a wild-type or modified group II intron encoded protein, wherein said open reading frame sequence is located upstream, or downstream of the modified group II intron sequence, and wherein expression of said group II intron encoded protein is regulated by the promoter which is operably linked to the modified group II intron sequence or by a second promoter which is operably linked to the open reading frame sequence; and b) maintaining the cell under in vitro conditions which allow for expression of the modified group II intron sequence and the open reading frame sequence, formation of RNP particles comprising a modified excised group II intron RNA which is encoded by the modified group II intron sequence and a group II intron encoded protein which is encoded by the open reading frame sequence, and insertion of the modified group II intron into the DNA target site; wherein the method results in increased insertion of said modified group II introns into the DNA target site in the host cell in vitro as compared to a method where the group II intron RNA lacks deletion of subdomains IVB1, IVB2, and IVB3. 2. A method of increasing insertion of modified group II introns into a DNA target site in a host cell in vitro, said method comprising: a) introducing a nucleic acid construct into the host cell, said construct comprising i.) a modified L1.LtrB intron sequence encoding a modified group II intron RNA, said modified group II intron RNA comprising an EBS1 sequence, an EBS2 sequence, a delta sequence, and a deletion of subdomains IVB1, IVB2, IVB3, wherein one or more of said EBS1, EBS2 or delta sequences is modified to provide a modified EBS1, EBS2, and delta sequence that base pairs with an IBS1, IBS2, and delta prime sequence, respectively, in the DNA target site; ii) a promoter for regulating transcription of said modified group II intron sequence, said promoter being operably linked to the modified L1.LtrB intron sequence; iii) a first flanking sequence upstream of the modified L1.LtrB intron sequence, said flanking sequence encoding a first hybridizing sequence which is complementary to the EBS1 or the modified EBS1 sequence contained in the modified group II intron RNA and a second flanking sequence downstream of the modified L1.LtrB sequence encoding a second hybridizing sequence which is complementary to the EBS2 or the modified EBS2 sequence contained in the modified group II intron RNA; and iv) an open reading frame sequence encoding a modified or wild-type LtrA protein, wherein said open reading frame sequence is located upstream, or downstream of the modified L1.LtrB intron sequence, and wherein expression of said LtrA protein is regulated by the promoter which is operably linked to the modified L1.LtrB intron sequence or by a second promoter which is operably linked to the open reading frame sequence; and b) maintaining the cell under in vitro conditions which allow for expression of the modified L1.LtrB intron sequence and the open reading frame sequence, formation of modified group II RNP particles and the modified or wild-type LtrA protein, and insertion of the modified group II intron into the DNA target site; wherein the method results in increased insertion of said modified group II introns into the DNA target site in the host cell in vitro as compared to a method where the group II intron RNA lacks deletion of subdomains IVB1, IVB2, and IVB3. 3. The method of claim 1 wherein the nucleic acid construct is introduced into the host cell via a viral vector. 4. The method of claim 1 wherein the nucleic acid construct is introduced into the host cell in association with a liposome. 5. The method of claim 1 wherein the nucleic acid construct is introduced into the host cell via a plasmid. 6. The method of claim 1 wherein the host cell is an archaebacterial or eubacterial cell. 7. The method of claim 1 wherein the host cell is a fungal cell, a plant cell or algae cell. 8. The method of claim 1 wherein the host cell is an animal cell. 9. The method of claim 1 wherein the group II intron encoded protein is modified at the N-terminus, the C-terminus, or internally and wherein the open reading frame encodes a fusion protein comprising a group II intron encoded protein linked to a purification tag, a detection tag or an intracellular localization signal. 10. A method of increasing insertion of modified group II introns into a DNA target site in a host cell in vitro, comprising: a) introducing a nucleic acid construct into the host cell, said construct comprising i.) a modified group II intron sequence encoding a modified group II intron RNA, said modified group II intron RNA comprising an EBS1 sequence, an EBS2 sequence, a delta sequence, and a deletion of subdomains IVB1, IVB2, IVB3, wherein one or more of said EBS1, EBS2 or delta sequences is modified to provide a modified EBS1, EBS2, and delta sequence that base pairs with an IBS1, IBS2, and delta prime sequence, respectively, in the DNA target site; ii) a promoter for regulating transcription of said modified group II intron sequence, said promoter being operably linked to the modified group II intron sequence; iii) a first flanking sequence upstream of the group II intron sequence, said flanking sequence encoding a first hybridizing sequence which is complementary to the EBS1 or the modified EBS1 sequence contained in said modified group II intron RNA and a second flanking sequence downstream of the modified group II intron sequence encoding a second hybridizing sequence which is complementary to the EBS2 or the modified EBS2 sequence contained in said modified group II intron RNA; and b) introducing a second nucleic acid construct into the cell, said second construct comprising an open reading frame sequence encoding a wild-type or modified group II intron encoded protein and a promoter which is operably linked to the open reading frame sequence; and c) maintaining the cell under in vitro conditions which allow for expression of the modified group II intron sequence and the open reading frame sequence, formation of RNP particles comprising a modified excised group II intron RNA which is encoded by the modified group II intron sequence and a group II intron encoded protein which is encoded by the open reading frame sequence, and insertion of the modified group II intron into the DNA target site; wherein the method results in increased insertion of said modified group II introns into a DNA target site in the host cell in vitro as compared to a method where the group II intron RNA lacks deletion of subdomains IVB1, IVB2, and IVB3. 11. The method of claim 10 wherein the group II intron encoded protein is modified at the N-terminus, the C-terminus, or internally and wherein the open reading frame encodes a fusion protein comprising a group II intron encoded protein linked to a purification tag, a detection tag, or an intracellular localization signal. 12. The method of claim 1, wherein the modified group II intron RNA comprises a modified EBS1 sequence. 13. The method of claim 1, wherein the modified group II intron RNA comprises a modified EBS2 sequence. 14. The method of claim 1, wherein the modified group II intron RNA comprises a modified delta sequence. 15. The method of claim 10 wherein the modified group II intron is a modified L1.LtrB intron, and wherein the open reading frame sequence encodes a wild-type or modified LtrA protein. 16. The method of claim 1, wherein the RNP particles prepared by said method have greater resistance to nucleolytic activity in the host cell than RNP particles comprising a group II intron RNA lacking deletion of subdomains IVB1, IVB2, and IVB3. 17. The method of claim 2, wherein the RNP particles prepared by said method have greater resistance to nucleolytic activity in the host cell than RNP particles comprising a group II intron RNA lacking deletion of subdomains IVB1, IVB2, and IVB3. 18. The method of claim 10, wherein the RNP particles prepared by said method have greater resistance to nucleolytic activity in the host cell than RNP particles comprising a group II intron RNA lacking deletion of subdomains IVB1, IVB2, and IVB3.

Details for Patent 7,592,161

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-10-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-10-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-10-15